Verona Pharma Plc (LON:VRP) is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage
Verona Pharma Plc (LON:VRP) is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly
By Keith Hiscock, CEO. The Office for National Statistics has just published its bi-annual report ‘Ownership of quoted shares for UK domiciled companies’ using 2014 data. For the first time,
Highlights this month: Alliance Pharma (APH) trading update of 13th July was positive and a new FD appointed. City of London Investment Group (CLIG) The July trading update was in
Although it can be seen on the daily chart of Verona Pharma PLC (:LON:VRP) that there has already been a significant recovery from the lowest levels of last
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
